SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-23-085303
Filing Date
2023-11-09
Accepted
2023-11-09 17:05:10
Documents
6
Period of Report
2023-11-30

Document Format Files

Seq Description Document Type Size
1 PROXY STATEMENT def14a1023_actinium.htm DEF 14A 1127991
2 GRAPHIC tactinium_logo.jpg GRAPHIC 134725
3 GRAPHIC tbarchart_001.jpg GRAPHIC 335455
4 GRAPHIC tbarchart_002.jpg GRAPHIC 299540
5 GRAPHIC tproxy_001.jpg GRAPHIC 1048906
6 GRAPHIC tproxy_002.jpg GRAPHIC 1199788
  Complete submission text file 0001213900-23-085303.txt   5287437
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 231393633
SIC: 2834 Pharmaceutical Preparations